Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

Executive Summary

'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.


Related Content

Coherus Knocks Out One Humira Patent But Others Block Biosimilars
Mylan Clears Runway For US Herceptin Biosimilar Launch
Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain
Express Scripts Projects Higher Spending In Inflammation, Diabetes, Cancer
Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions
Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
AbbVie Rival Boehringer Persuades PTAB To Reexamine Humira Patent


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst